Identification of programmed cell death-related subtypes reveals immune heterogeneity and therapeutic divergence in colon cancer
This study defines a novel molecular subtype for COAD, linking PCD dysregulation to distinct TME remodeling and therapeutic outcomes. Targeting the MDK-SDC2 axis with agents such as sunitinib may offer a promising strategy to overcome stromal-mediated immunotherapy resistance in the most lethal PCDS3 tumors.
Authors
- Ruohan Zhang (ORCID: https://orcid.org/0000-0002-7099-7067)
- Kening Li (ORCID: https://orcid.org/0000-0001-9750-1810)
- Mengyan Zhu (ORCID: https://orcid.org/0000-0003-2953-8309)
- Yingli Lv
- Peng Xia
- Wei Wu
- Quanzhong Liu
- Ying Qu
- Bin Huang
- Lingxiang Wu
Institutions
- Harbin Medical University (CN)
- Capital Medical University (CN)
- Beijing Tian Tan Hospital (CN)
- Jiangsu Cancer Hospital (CN)
- Southeast University (CN)
- Nanjing Medical University (CN)
Publication Details
- Journal
- Theranostics
- Published
- 2026-02-18
- DOI
- https://doi.org/10.7150/thno.126314
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00